Laurion Capital Management LP Boosts Stake in Kalvista Pharmaceuticals Inc (KALV)

Laurion Capital Management LP lifted its position in shares of Kalvista Pharmaceuticals Inc (NASDAQ:KALV) by 94.9% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 58,871 shares of the specialty pharmaceutical company’s stock after acquiring an additional 28,670 shares during the quarter. Laurion Capital Management LP’s holdings in Kalvista Pharmaceuticals were worth $1,685,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Flinton Capital Management LLC purchased a new stake in shares of Kalvista Pharmaceuticals in the 4th quarter valued at about $26,000. Barclays PLC raised its holdings in shares of Kalvista Pharmaceuticals by 88,319.7% during the 4th quarter. Barclays PLC now owns 62,778 shares of the specialty pharmaceutical company’s stock valued at $1,240,000 after buying an additional 62,707 shares in the last quarter. Polar Capital LLP purchased a new position in shares of Kalvista Pharmaceuticals during the 4th quarter valued at about $1,558,000. Vanguard Group Inc. raised its holdings in shares of Kalvista Pharmaceuticals by 152.4% during the 3rd quarter. Vanguard Group Inc. now owns 296,581 shares of the specialty pharmaceutical company’s stock valued at $6,558,000 after buying an additional 179,092 shares in the last quarter. Finally, Fosun International Ltd purchased a new position in shares of Kalvista Pharmaceuticals during the 4th quarter valued at about $2,444,000. Institutional investors own 79.52% of the company’s stock.

NASDAQ KALV opened at $23.14 on Thursday. Kalvista Pharmaceuticals Inc has a twelve month low of $7.73 and a twelve month high of $34.92. The company has a market cap of $404.11 million, a P/E ratio of -15.12 and a beta of 2.32.



Kalvista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.23) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.45) by $0.22. Kalvista Pharmaceuticals had a negative return on equity of 19.12% and a negative net margin of 70.08%. The company had revenue of $3.89 million for the quarter, compared to analyst estimates of $3.97 million. On average, research analysts predict that Kalvista Pharmaceuticals Inc will post -1.43 EPS for the current fiscal year.

In related news, major shareholder Venrock Healthcare Capital Par sold 500,000 shares of Kalvista Pharmaceuticals stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $28.75, for a total transaction of $14,375,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Benjamin L. Palleiko sold 1,073 shares of Kalvista Pharmaceuticals stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $25.51, for a total value of $27,372.23. Following the sale, the chief financial officer now owns 33,573 shares in the company, valued at $856,447.23. The disclosure for this sale can be found here. Insiders have sold 901,521 shares of company stock worth $25,597,568 over the last 90 days. 38.40% of the stock is currently owned by corporate insiders.

A number of equities analysts have commented on the company. ValuEngine raised Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. Needham & Company LLC assumed coverage on Kalvista Pharmaceuticals in a research note on Wednesday, March 20th. They issued a “buy” rating and a $35.00 price target on the stock. BidaskClub raised Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, March 1st. Roth Capital lifted their price objective on Kalvista Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Wednesday, May 15th. Finally, Zacks Investment Research lowered Kalvista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $30.60.

WARNING: This story was published by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://dakotafinancialnews.com/2019/05/23/laurion-capital-management-lp-boosts-stake-in-kalvista-pharmaceuticals-inc-kalv.html.

Kalvista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

See Also: Why does the United States have a lingering trade deficit?

Want to see what other hedge funds are holding KALV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kalvista Pharmaceuticals Inc (NASDAQ:KALV).

Institutional Ownership by Quarter for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.